ImmuPharma plc (LON:IMM – Get Free Report) fell 8.2% during mid-day trading on Wednesday . The stock traded as low as GBX 4.30 ($0.05) and last traded at GBX 4.59 ($0.06). 7,105,372 shares traded hands during mid-day trading, a decline of 68% from the average session volume of 22,291,344 shares. The stock had previously closed at GBX 5 ($0.06).
ImmuPharma Trading Up 23.8 %
The company has a market cap of £20.11 million, a price-to-earnings ratio of -483.00 and a beta of 1.53. The business has a 50-day moving average price of GBX 2.46 and a 200 day moving average price of GBX 1.95.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- Low PE Growth Stocks: Unlocking Investment Opportunities
- IBM’s AI Bet Pays Off—What’s Next for Investors?
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- 3 Reasons to Treat AMD’s Drop as an Entry Opportunity
- What Are Trending Stocks? Trending Stocks Explained
- Qualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
